Press releases
Coartem® Dispersible is now being distributed in 39 countries
Pioneering MMV research published in PLoS Medicine compares the activity of antimalarial medicines at every step of the parasite’s lifecycle
This new antimalarial is indicated for P. falciparum and blood stage P. vivax malaria
Carefully selected by experienced chemists these free compounds are set to propel malaria drug discovery to the next level
Fourth annual G-FINDER survey report is released
This fixed-dose combination of dihydroartemisinin and piperaquine is administered once a day for 3 days
Novartis and MMV have identified a new class of compounds that targets both the blood- and liver-stage infections of malaria
Dundee and MMV make rapid progress towards a potential new treatment for malaria
This WANECAM antimalarials study is mainly funded by EDCTP, and co-funded by MMV
EU-funded report recommends
